STOCK TITAN
  1. Home
  2. SEC-Filings
  3. TERN

Terns Pharmaceuticals, Inc. SEC Filings

TERN NASDAQ

Welcome to our dedicated page for Terns Pharmaceuticals SEC filings (Ticker: TERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading a biotech filing can feel like decoding a chemistry textbook—especially when Terns Pharmaceuticals links Phase I data, milestone payments and dilution risk in one 300-page document. Investors hunting for pipeline updates or wondering if fresh capital is needed often scroll for hours before finding the answers.

Stock Titan’s AI changes the workflow. Our platform ingests every Terns Pharmaceuticals SEC filing the moment it hits EDGAR and produces plain-English highlights. Need the Terns Pharmaceuticals quarterly earnings report 10-Q filing? We flag trial expenses and cash runway in seconds. Curious about Terns Pharmaceuticals insider trading Form 4 transactions? Get real-time alerts and charts. For deeper dives, our summaries link directly to the page where each disclosure lives, so you can move from headline to source without manual PDF searches.

Here’s what you can explore instantly:

  • Terns Pharmaceuticals annual report 10-K simplified—drug pipeline milestones, risk factors and licensing revenue
  • Terns Pharmaceuticals Form 4 insider transactions real-time—executive stock transactions and option grants
  • Terns Pharmaceuticals proxy statement executive compensation—how trial success metrics drive bonuses
  • Terns Pharmaceuticals 8-K material events explained—clinical data releases, financing rounds and collaboration news
  • Terns Pharmaceuticals earnings report filing analysis—quarter-over-quarter R&D trends

Whether you’re monitoring the allosteric BCR-ABL program or comparing GLP-1 development costs, understanding Terns Pharmaceuticals SEC documents with AI means spending minutes, not days, on due diligence.

Filing

[Form 4] Terns Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Terns Pharmaceuticals (TERN)?

The current stock price of Terns Pharmaceuticals (TERN) is $3.83 as of June 28, 2025.

What is the market cap of Terns Pharmaceuticals (TERN)?

The market cap of Terns Pharmaceuticals (TERN) is approximately 321.4M.

What is the primary focus of Terns Pharmaceuticals?

Terns Pharmaceuticals is focused on developing molecularly-targeted, oral small molecule drugs. Its research is primarily aimed at addressing serious diseases such as liver disorders, oncology conditions, obesity, and chronic myeloid leukemia.

How does Terns generate its revenue?

The company operates through a capital-efficient drug discovery and clinical development model. It advances a comprehensive portfolio of clinical stage candidates, aiming to address significant unmet medical needs without relying on large-scale commercialization revenue at early stages.

What distinguishes TERN-701 in its pipeline?

TERN-701 is an allosteric BCR-ABL inhibitor developed for the treatment of CML. It differentiates itself by targeting a unique binding pocket, potentially offering improved safety, tolerability, and simplified dosing compared to traditional active-site inhibitors.

How does the company approach its drug discovery process?

Terns integrates advanced structure-based drug design, quantitative structure-activity relationship models, and robust medicinal chemistry. This comprehensive approach helps optimize candidate compounds for better metabolic stability and effective target engagement.

In what therapeutic areas does Terns Pharmaceuticals operate?

The company operates primarily in the realms of liver diseases, oncology, obesity, and hematologic conditions, including chronic myeloid leukemia. This diversity in focus areas underlines its commitment to addressing significant, unmet clinical needs.

What role does global collaboration play in the company’s strategy?

Terns benefits from a dual operational base in the United States and China. This international presence enhances its clinical development capabilities, regulatory expertise, and overall operational efficiency in advancing its pipeline.

How is Terns addressing the challenges in the obesity treatment market?

Through its development of a small molecule GLP-1 receptor agonist, Terns aims to provide meaningful weight loss with a simplified dosing regimen. The candidate is designed to improve patient compliance while maintaining robust efficacy and tolerability.

What are the key strengths highlighted in Terns Pharmaceuticals’ clinical programs?

Key strengths include the novel mechanisms of action, optimized pharmacokinetic profiles, and a disciplined clinical execution model. These factors combine to support a compelling narrative of innovative, targeted therapy development focused on critical diseases.
Stock TERN logo
Terns Pharmaceuticals, Inc.

NASDAQ:TERN

TERN Rankings

#3526 Ranked by Market Cap
N/A Ranked by Dividends

TERN Stock Data

321.40M
79.52M
0.26%
108.17%
7.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY